Key result
Optimized vascular-targeted nanocarriers improve drug delivery to atherosclerotic plaques using active and passive strategies.
Answers are grounded in this paper and cite their sources.
Vascular-targeted nanocarriers are an attractive option for the treatment of a number of cardiovascular diseases, as they allow for more specific delivery and increased efficacy of many small molecule drugs. However, immune clearance, limited cellular uptake, and particle-cell dynamics in blood flow can hinder nanocarrier efficacy in many applications. This review aims to investigate successful strategies for the use of vascular-targeted nanocarriers in the treatment of cardiovascular diseases such as atherosclerosis. In particular, the review will highlight strategies employed for actively targeting the components of the atherosclerotic plaque, including endothelial cells, macrophages, and platelets and passive targeting via endothelial permeability, as well as design specifications (such as size, shape, and density) aimed at enhancing the ability of nanocarriers to reach the vascular wall. WIREs Nanomed Nanobiotechnol 2016, 8:909-926. doi: 10.1002/wnan.1414 For further resources related to this article, please visit the WIREs website.
No takes yet. Share an insight, caveat, or question.
Kelley et al. (2016) conducted a review in Atherosclerosis and other vascular diseases. Vascular-targeted nanocarriers was evaluated. Vascular-targeted nanocarriers utilize active and passive targeting strategies alongside optimized size, shape, and density to improve drug delivery to atherosclerotic plaques.
Synapse has enriched 10 related papers. Consider them for comparative context: